TIDMRENX

RNS Number : 9355D

Renalytix AI PLC

25 February 2020

Renalytix AI plc

("RenalytixAI", the "Company" or the "Group")

Conference attendance

CEO speaking at Cowen 40th Annual Health Care Conference

Renalytix AI plc (LSE : RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference, which runs from the 1-4 March 2020, hosted at Boston Marriott Copley Place, Boston, USA.

The conference brings together top institutional investors and leading companies operating in the Health Care space.

James McCullough, CEO of Renalytix, will be presenting on Tuesday 3 March at 8.40am - 9.10am in Simmons, 3(rd) Floor.

The presentation will be made available on the Company's website shortly after here:

https://renalytixai.com/investors/company-presentation/ and no new material or trading information will be provided.

For further information, please contact:

 
Renalytix AI plc                                                                    www.renalytixai.com 
James McCullough, CEO                                                                   Via Walbrook PR 
 
Stifel (Nominated Adviser & Joint Broker)                                            Tel: 020 7710 7600 
Alex Price / Jonathan Senior / Ben Maddison 
 
N+1 Singer (Joint Broker)                                                            Tel: 020 7496 3000 
Aubrey Powell / George Tzimas (Corporate Finance) 
Tom Salvesen / Mia Gardner (Corporate Broking) 
 
Walbrook PR Limited                                      Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Cawthorne                                          Mob: 07980 541 893 / 07584 391 
                                                                                                    303 
 
 

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease. It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information, visit renalytixai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRADZGZZFDDGGZM

(END) Dow Jones Newswires

February 25, 2020 02:00 ET (07:00 GMT)

Grafico Azioni Renalytix (LSE:RENX)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Renalytix
Grafico Azioni Renalytix (LSE:RENX)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Renalytix